NASDAQ:CTIC

CTI BioPharma Competitors

$2.43
-0.15 (-5.81 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.42
Now: $2.43
$2.55
50-Day Range
$2.51
MA: $3.00
$3.33
52-Week Range
$0.86
Now: $2.43
$4.13
Volume1.15 million shs
Average Volume919,443 shs
Market Capitalization$186.35 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86

Competitors

CTI BioPharma (NASDAQ:CTIC) Vs. LXRX, ICPT, ESPR, ORIC, VERU, and ZIOP

Should you be buying CTIC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to CTI BioPharma, including Lexicon Pharmaceuticals (LXRX), Intercept Pharmaceuticals (ICPT), Esperion Therapeutics (ESPR), ORIC Pharmaceuticals (ORIC), Veru (VERU), and ZIOPHARM Oncology (ZIOP).

Lexicon Pharmaceuticals (NASDAQ:LXRX) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

84.6% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 52.5% of CTI BioPharma shares are held by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of CTI BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Lexicon Pharmaceuticals and CTI BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%
CTI BioPharmaN/A-126.77%-66.68%

Valuation & Earnings

This table compares Lexicon Pharmaceuticals and CTI BioPharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lexicon Pharmaceuticals$322.07 million2.27$130.13 million$1.353.76
CTI BioPharma$3.35 million55.63$-40,020,000.00($0.69)-3.52

Lexicon Pharmaceuticals has higher revenue and earnings than CTI BioPharma. CTI BioPharma is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Lexicon Pharmaceuticals and CTI BioPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Lexicon Pharmaceuticals06202.25
CTI BioPharma00403.00

Lexicon Pharmaceuticals currently has a consensus target price of $9.40, indicating a potential upside of 85.40%. CTI BioPharma has a consensus target price of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe CTI BioPharma is more favorable than Lexicon Pharmaceuticals.

Summary

CTI BioPharma beats Lexicon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Intercept Pharmaceuticals (NASDAQ:ICPT) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Intercept Pharmaceuticals and CTI BioPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intercept Pharmaceuticals115802.29
CTI BioPharma00403.00

Intercept Pharmaceuticals currently has a consensus target price of $50.6957, indicating a potential upside of 128.98%. CTI BioPharma has a consensus target price of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe CTI BioPharma is more favorable than Intercept Pharmaceuticals.

Profitability

This table compares Intercept Pharmaceuticals and CTI BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%
CTI BioPharmaN/A-126.77%-66.68%

Institutional & Insider Ownership

85.8% of Intercept Pharmaceuticals shares are held by institutional investors. Comparatively, 52.5% of CTI BioPharma shares are held by institutional investors. 23.7% of Intercept Pharmaceuticals shares are held by company insiders. Comparatively, 6.9% of CTI BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Intercept Pharmaceuticals and CTI BioPharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intercept Pharmaceuticals$252 million2.90$-344,680,000.00($10.89)-2.03
CTI BioPharma$3.35 million55.63$-40,020,000.00($0.69)-3.52

CTI BioPharma has lower revenue, but higher earnings than Intercept Pharmaceuticals. CTI BioPharma is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Intercept Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Esperion Therapeutics (NASDAQ:ESPR) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

Risk & Volatility

Esperion Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares Esperion Therapeutics and CTI BioPharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Esperion Therapeutics$148.36 million4.90$-97,170,000.00($3.59)-7.25
CTI BioPharma$3.35 million55.63$-40,020,000.00($0.69)-3.52

CTI BioPharma has lower revenue, but higher earnings than Esperion Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than CTI BioPharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

52.5% of CTI BioPharma shares are owned by institutional investors. 7.7% of Esperion Therapeutics shares are owned by insiders. Comparatively, 6.9% of CTI BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Esperion Therapeutics and CTI BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Esperion Therapeutics-46.15%-629.88%-41.43%
CTI BioPharmaN/A-126.77%-66.68%

Analyst Recommendations

This is a summary of recent ratings for Esperion Therapeutics and CTI BioPharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Esperion Therapeutics24312.30
CTI BioPharma00403.00

Esperion Therapeutics currently has a consensus target price of $50.60, indicating a potential upside of 94.47%. CTI BioPharma has a consensus target price of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe CTI BioPharma is more favorable than Esperion Therapeutics.

Summary

CTI BioPharma beats Esperion Therapeutics on 10 of the 15 factors compared between the two stocks.

ORIC Pharmaceuticals (NASDAQ:ORIC) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.

Earnings and Valuation

This table compares ORIC Pharmaceuticals and CTI BioPharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ORIC PharmaceuticalsN/AN/AN/AN/AN/A
CTI BioPharma$3.35 million55.63$-40,020,000.00($0.69)-3.52

ORIC Pharmaceuticals has higher earnings, but lower revenue than CTI BioPharma.

Profitability

This table compares ORIC Pharmaceuticals and CTI BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ORIC PharmaceuticalsN/AN/AN/A
CTI BioPharmaN/A-126.77%-66.68%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for ORIC Pharmaceuticals and CTI BioPharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ORIC Pharmaceuticals01602.86
CTI BioPharma00403.00

ORIC Pharmaceuticals currently has a consensus price target of $43.7143, indicating a potential upside of 122.01%. CTI BioPharma has a consensus price target of $7.25, indicating a potential upside of 198.35%. Given CTI BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe CTI BioPharma is more favorable than ORIC Pharmaceuticals.

Institutional and Insider Ownership

73.4% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 52.5% of CTI BioPharma shares are held by institutional investors. 6.9% of CTI BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

CTI BioPharma (NASDAQ:CTIC) and Veru (NASDAQ:VERU) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares CTI BioPharma and Veru's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CTI BioPharma$3.35 million55.63$-40,020,000.00($0.69)-3.52
Veru$42.59 million16.48$-18,970,000.00($0.11)-88.73

Veru has higher revenue and earnings than CTI BioPharma. Veru is trading at a lower price-to-earnings ratio than CTI BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CTI BioPharma and Veru's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CTI BioPharmaN/A-126.77%-66.68%
Veru-44.55%-23.72%-13.80%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CTI BioPharma and Veru, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CTI BioPharma00403.00
Veru00403.00

CTI BioPharma currently has a consensus target price of $7.25, suggesting a potential upside of 198.35%. Veru has a consensus target price of $19.25, suggesting a potential upside of 97.23%. Given CTI BioPharma's higher probable upside, research analysts plainly believe CTI BioPharma is more favorable than Veru.

Risk & Volatility

CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Veru has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Institutional and Insider Ownership

52.5% of CTI BioPharma shares are owned by institutional investors. Comparatively, 23.3% of Veru shares are owned by institutional investors. 6.9% of CTI BioPharma shares are owned by insiders. Comparatively, 26.1% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CTI BioPharma (NASDAQ:CTIC) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Earnings & Valuation

This table compares CTI BioPharma and ZIOPHARM Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CTI BioPharma$3.35 million55.63$-40,020,000.00($0.69)-3.52
ZIOPHARM Oncology$150,000.004,677.12$-117,800,000.00($0.34)-9.59

CTI BioPharma has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than CTI BioPharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CTI BioPharma and ZIOPHARM Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CTI BioPharmaN/A-126.77%-66.68%
ZIOPHARM OncologyN/A-48.49%-43.53%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for CTI BioPharma and ZIOPHARM Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CTI BioPharma00403.00
ZIOPHARM Oncology03202.40

CTI BioPharma currently has a consensus target price of $7.25, suggesting a potential upside of 198.35%. ZIOPHARM Oncology has a consensus target price of $5.90, suggesting a potential upside of 80.98%. Given CTI BioPharma's stronger consensus rating and higher probable upside, research analysts plainly believe CTI BioPharma is more favorable than ZIOPHARM Oncology.

Risk & Volatility

CTI BioPharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500.

Institutional and Insider Ownership

52.5% of CTI BioPharma shares are owned by institutional investors. Comparatively, 48.0% of ZIOPHARM Oncology shares are owned by institutional investors. 6.9% of CTI BioPharma shares are owned by insiders. Comparatively, 2.3% of ZIOPHARM Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

CTI BioPharma beats ZIOPHARM Oncology on 8 of the 13 factors compared between the two stocks.


CTI BioPharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.07-5.9%$731.88 million$322.07 million-4.83Decrease in Short Interest
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.14-0.1%$730.97 million$252 million-2.26
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$26.02-3.6%$727.08 million$148.36 million-6.76Gap Up
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$19.69-9.5%$722.53 millionN/A0.00Increase in Short Interest
Veru logo
VERU
Veru
1.4$9.76-6.0%$701.86 million$42.59 million-34.86News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.26-1.8%$701.57 million$150,000.00-4.66Gap Down
Chimerix logo
CMRX
Chimerix
1.3$8.17-3.4%$700.00 million$12.52 million-14.33Analyst Report
Increase in Short Interest
News Coverage
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.74-2.9%$695.97 million$2.22 million-16.12News Coverage
Ardelyx logo
ARDX
Ardelyx
1.6$7.03-5.8%$693.72 million$5.28 million-6.96Increase in Short Interest
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$27.20-1.1%$679.21 million$19.56 million-19.57News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.16-1.1%$643.91 million$143.01 million-1.18
OrganiGram logo
OGI
OrganiGram
1.6$2.77-10.1%$643.39 million$64.61 million-4.07Decrease in Short Interest
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.42-3.8%$635.95 millionN/A-2.37Increase in Short Interest
Kadmon logo
KDMN
Kadmon
1.8$3.68-0.5%$632.29 million$5.09 million-6.13
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.82-15.1%$630.42 millionN/A-4.75Analyst Upgrade
News Coverage
Gap Down
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$17.53-0.5%$627.73 million$6.83 million-18.07
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$27.00-5.1%$623.43 million$13.80 million-13.04
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$25.23-3.6%$613.29 million$12.69 million-12.13Increase in Short Interest
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.94-2.9%$610.50 million$9.64 million-5.20
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$35.67-1.2%$597.37 millionN/A-16.51
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$13.60-9.0%$576.33 million$17.26 million-3.78Earnings Announcement
Analyst Revision
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$11.80-4.4%$572.96 millionN/A-6.05
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$17.76-11.8%$572.94 millionN/A-9.45
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$17.11-0.2%$565.13 million$1.19 million-7.13
Evolus logo
EOLS
Evolus
1.1$12.72-6.8%$556.28 million$34.92 million-6.27
Inventiva logo
IVA
Inventiva
0.0$14.35-0.6%$554.34 millionN/A0.00
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.8$11.71-2.8%$553.26 millionN/A-9.08Increase in Short Interest
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.18-0.1%$553.04 millionN/A-5.28News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.5$20.15-3.6%$551.43 million$8 million-7.44News Coverage
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.4$41.32-0.6%$546.13 million$195.89 million118.06
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.08-0.3%$543.38 million$26.74 million17.70
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.09-5.5%$525.67 million$59.29 million-20.60Increase in Short Interest
Provention Bio logo
PRVB
Provention Bio
1.6$8.23-2.8%$521.58 millionN/A-5.52Analyst Report
Increase in Short Interest
News Coverage
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.48-0.7%$520.09 million$36.63 million-6.45News Coverage
Gap Down
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.28-3.1%$514.63 million$49.65 million-1.80
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.15-1.5%$514.26 million$25 million-18.69Analyst Report
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.69-3.2%$513.07 millionN/A-4.52
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.99-10.9%$511.73 millionN/A-4.03News Coverage
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.29-3.7%$504.53 millionN/A-7.99News Coverage
Akouos logo
AKUS
Akouos
1.6$14.51-4.4%$499.17 millionN/A0.00
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.86-1.0%$497.08 million$58.12 million-16.11Decrease in Short Interest
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.44-4.0%$493.45 million$59.22 million42.20
XBiotech logo
XBIT
XBiotech
1.0$16.75-1.2%$493.44 millionN/A1.16
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.38-1.8%$485.50 millionN/A-2.55
AC Immune logo
ACIU
AC Immune
1.3$6.62-3.8%$476.22 million$111.75 million-7.36
89bio logo
ETNB
89bio
1.6$23.80-10.4%$474.72 millionN/A-4.71
Altimmune logo
ALT
Altimmune
1.9$12.57-2.6%$466.98 million$5.80 million-6.32Increase in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.91-17.0%$458.09 million$40,000.00-1.47High Trading Volume
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.98-2.7%$457.44 million$335 million-1.01
This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.